Depression raises risk of poor outcomes for blacks with heart failure

American Heart Association Rapid Access Journal Report

April 21, 2015 Categories: Heart News

Study Highlights

  • Even moderate depressive symptoms may raise the risk of hospitalization or death in black heart failure patients.
  • Black heart failure patients with worsening symptoms of depression over 3 months had a 33 percent higher risk of dying or being hospitalized compared to patients with stable depressive symptoms.

Embargoed until 3 p.m. CT/4 p.m. ET Tuesday, April 21, 2015

DALLAS, April 21, 2014 — Among black heart failure patients, moderate depression may increase the risk of being hospitalized or dying, according to research in the American Heart Association journal Circulation: Heart Failure.

Comparing outcomes of 747 blacks to 1,420 whites with heart failure using a patient-reported scale of depressive symptoms, researchers found:

  • Even moderate depressive symptoms may raise the risk of black heart failure patients being hospitalized or dying.
  • Blacks with levels of depressive symptoms even below the levels commonly used to diagnose clinical depression had increased risk for death or hospitalization.
  • Black patients had a 33 percent higher risk of dying or being hospitalized when depressive symptoms worsened over three months compared to patients with stable depressive symptoms.

“Identifying and treating even modest symptoms of depression in black patients with heart failure could help to improve patient outcomes,” said Robert Mentz, M.D., study author and cardiologist and assistant professor of medicine at Duke University Medical Center in Durham, N.C.

Almost 6 million American adults suffer heart failure, a chronic, progressive condition in which the heart doesn’t effectively pump blood to the body.

In one of the first studies to specifically examine depression in black versus white patients with heart failure, participants answered questions about their emotional health based on the Beck Depression Inventory II, which is a validated test for measuring depression. Scoring 14 or higher supports a diagnosis of clinical depression.

Depressive symptoms, such as difficulty with concentration, fatigue or lack of energy, feelings of hopelessness and/or helplessness, were gauged at the beginning of the study and three months later. About one-third of the black participants reported symptoms consistent with clinical depression at the study’s start.

Mentz’ team analyzed the implications of baseline depressive symptoms and changes in these symptoms related to participants’ health outcomes including hospitalization or death. The researchers factored out variables such as age, gender, smoking, other medical conditions and heart failure severity. Baseline depressive symptoms and worsening of symptoms over time were linked with worse outcomes in patients, especially among blacks.

Although depression is common among both races, black heart failure patients are less likely to get treated. In the study, only about 22 percent of blacks with levels of depressive symptoms supporting a diagnosis of clinical depression were taking anti-depressant medications, compared to 42 percent of whites.

“These results suggest the potential importance of screening all heart failure patients with simple questions about their mood and depression at every health appointment, so their depression can be identified and treated,” Mentz said.

Co-authors are Michael Babyak, Ph.D.; Vera Bittner, M.D., M.S.P.H.; Jerome Fleg, M.D.; Steven Keteyian, Ph.D.; Ann Swank, Ph.D.; Ileana Piña, M.D., M.P.H.; William Kraus, M.D.; David Whellan, M.D., M.H.S.; Christopher O’Connor, M.D.; and James Blumenthal, Ph.D. Author disclosures are on the manuscript.

Additional Resources:

###

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.

For Media Inquiries: (214) 706-1173

Darcy Spitz: (212) 878-5940; darcy.spitz@heart.org

Julie Del Barto (broadcast): (214) 706-1330; julie.delbarto@heart.org

For Public Inquiries: (800)-AHA-USA1 (242-8721)

heart.org and strokeassociation.org

Life is why we fund scientific breakthroughs that save and improve lives.